BRISBANE, Calif. (AP) _ Sangamo Therapeutics Inc. (SGMO) on Thursday reported a loss of $47.7 million in its third quarter.

On a per-share basis, the Brisbane, California-based company said it had a loss of 33 cents.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.

The drug developer posted revenue of $28.6 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $27.2 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SGMO at https://www.zacks.com/ap/SGMO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News